Skip to main content
Journal cover image

Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Publication ,  Journal Article
Moore, KN; Tritchler, D; Kaufman, KM; Lankes, H; Quinn, MCJ; Ovarian Cancer Association Consortium, ; Van Le, L; Berchuck, A; Backes, FJ ...
Published in: Gynecol Oncol
November 2017

OBJECTIVE: This study evaluated single nucleotide polymorphisms (SNPs) associated with progression free (PFS) and overall survival (OS) in patients with advanced stage serous EOC. METHODS: Patients enrolled in GOG-172 and 182 who provided specimens for translational research and consent were included. Germline DNA was evaluated with the Illumina's HumanOMNI1-Quad beadchips and scanned using Illumina's iScan optical imaging system. SNPs with allele frequency>0.05 and genotyping rate>0.98 were included. Analysis of SNPs for PFS and OS was done using Cox regression. Statistical significance was determined using Bonferroni corrected p-values with genomic control adjustment. RESULTS: The initial GWAS analysis included 1,124,677 markers in 396 patients. To obtain the final data set, quality control checks were performed and limited to serous tumors and self-identified Caucasian race. In total 636,555 SNPs and 289 patients passed all the filters. The pre-specified statistical level of significance was 7.855e-08. No SNPs met this criteria for PFS or OS, however, two SNPs were close to significance (rs10899426 p-2.144e-08) (rs6256 p-9.774e-07) for PFS and 2 different SNPs were identified (rs295315 p-7.536e-07; rs17693104 p-7.734e-07) which were close to significance for OS. CONCLUSIONS: Using the pre-specified level of significance of 1×10-08, we did not identify any SNPs of statistical significance for OS or PFS, however several were close. The SNP's identified in this GWAS study will require validation and these preliminary findings may lead to identification of novel pathways and biomarkers.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

November 2017

Volume

147

Issue

2

Start / End Page

396 / 401

Location

United States

Related Subject Headings

  • Randomized Controlled Trials as Topic
  • Prognosis
  • Polymorphism, Single Nucleotide
  • Peritoneal Neoplasms
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
  • Humans
  • Genome-Wide Association Study
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Moore, K. N., Tritchler, D., Kaufman, K. M., Lankes, H., Quinn, M. C. J., Ovarian Cancer Association Consortium, ., … Birrer, M. J. (2017). Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol, 147(2), 396–401. https://doi.org/10.1016/j.ygyno.2017.08.024
Moore, Kathleen N., David Tritchler, Kenneth M. Kaufman, Heather Lankes, Michael C. J. Quinn, Michael C. J. Ovarian Cancer Association Consortium, Linda Van Le, et al. “Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.Gynecol Oncol 147, no. 2 (November 2017): 396–401. https://doi.org/10.1016/j.ygyno.2017.08.024.
Moore KN, Tritchler D, Kaufman KM, Lankes H, Quinn MCJ, Ovarian Cancer Association Consortium, et al. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 Nov;147(2):396–401.
Moore KN, Tritchler D, Kaufman KM, Lankes H, Quinn MCJ, Ovarian Cancer Association Consortium, Van Le L, Berchuck A, Backes FJ, Tewari KS, Lee RB, Kesterson JP, Wenham RM, Armstrong DK, Krivak TC, Bookman MA, Birrer MJ. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 Nov;147(2):396–401.
Journal cover image

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

November 2017

Volume

147

Issue

2

Start / End Page

396 / 401

Location

United States

Related Subject Headings

  • Randomized Controlled Trials as Topic
  • Prognosis
  • Polymorphism, Single Nucleotide
  • Peritoneal Neoplasms
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
  • Humans
  • Genome-Wide Association Study